Notes in Blood Meds (11/7)

To Subscribe, use this Key

Status	Last Update	Fields
Published	11/11/2023	Iron supplements
Published	11/11/2023	{{c1::Constipation}} is very common adverse effect of iron supplementation
Published	11/11/2023	Sulfate salts are not well absorbed with {{c1::increased}} gastric pH
Published	11/11/2023	Physiologic Iron elimination
Published	11/11/2023	{{c1::Deferoxamine}} is an antidote for iron toxicity by {{c2::chelating}} circulating iron, increasing {{c2::renal excretion}}
Published	11/11/2023	Symptoms of Iron toxicity
Published	11/11/2023	{{c1::Gastric bypass}} can cause loss of {{c2::intrinsic factor}} and require {{c2::B12}} supplementation
Published	11/11/2023	{{c1::Deferasirox}} can be administered orally to treat {{c2::chronic iron overload}}
Published	11/11/2023	{{c1::Deferasirox}} binds to iron and eliminates the complex through the {{c2::feces}}
Published	11/11/2023	{{c1::Folic acid}} is a cofactor with {{c1::B12 (cobalamin)}} for {{c2::DNA synthesis}}
Published	11/11/2023	{{c1::Folic acid}} deficiency can result in {{c2::spina bifida}} or {{c2::anecephaly}}
Published	11/11/2023	Folic acid supplementation may correct {{c1::anemia}}, but {{c1::B12 deficiency}}
Published	11/11/2023	Erythropoiesis stimulating agents (ESAs)  are dosed according to {{c1::hemoglobin}} levels
Published	11/11/2023	{{c1::Erythropoietin (Epoietin)}}& {{c1::darbepoietin (Aranesp)}} are glycoprotein hormone produced by peritubular cells in kidney that simul…
Published	11/11/2023	Potential complications of {{c1::Erythropoiesis stimulating agents (ESAs)}} are {{c1::hypertension}} & {{c1::thrombosis}}
Published	11/11/2023	{{c1::Filgrastim (G-CSF)}} is a growth factor used specifically to stimulate {{c2::neutrophil}} activity
Published	11/11/2023	Sargramostim is {{c1::Granulocyte-monocyte colony-stimulating factor (GM-CSF)}}
Published	11/11/2023	{{c2::oprelvekin}} ⇒ {{c1::IL-11 receptor}} agonist {{c2::romiplostim}} ⇒ {{c1::thombopoetin}} peptide mimetic
Status	Last Update	Fields